Conditions: Healthy
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 25
Healthy volunteers: yes

Brief summary:
* To investigate the influence of different doses of BI 1026706 on the primary endpoint (PtP-amplitude LEP in UV skin) compared to placebo.
* The comparison of both doses of BI 1026706 to celecoxib in the UVB treatment.
* Comparison of both doses of BI 1026706 to placebo and pregabalin in the capsaicin treatment
* Exploration of the pharmacokinetics of BI 1026706
* Exploration of safety and tolerability of BI 1026706

Detailed description:

Arms:
arm 1: BI 1026706 plus matching placebo to BI 1026706 Powder for Oral Solution (PfOS) and placebo tablet arm 2: BI 1026706 and placebo tablet arm 3: Matching placebo to BI 1026706 PfOS and placebo tablet arm 4: Celecoxib hard capsule as active comparator plus matching placebo to BI 1026706 PfOS arm 5: Pregabalin hard capsule as active comparator plus matching placebo to BI 1026706 PfOS

Interventions: intervention 1: Placebo to BI 1026706 intervention 2: Pregabalin intervention 3: BI 1026706 intervention 4: Celecoxib
Intervention descriptions: intervention 1: Placebo tablet intervention 2: Pregabalin hard capsule intervention 3: BI 1026706 oral solution intervention 4: Celecoxib hard capsule

Protocol document: